23rd Jul 2008 12:36
Stock Exchange announcement
FOR release: Wednesday 23 July 2008
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Results of AGM
23 July 2008: At the Annual General Meeting of Celsis, held today, all resolutions were duly passed.
|
Enquiries: |
|
|
Celsis International plc |
Tel: +44 (0) 1223 598 428 |
|
Jay LeCoque, Chief Executive Officer |
|
|
Jenny Woolway, Corporate Communications |
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
David Yates |
|
|
Jonathan Birt |
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.
Related Shares:
Celadon Pharmaceuticals